EPISODE · Mar 11, 2026 · 11 MIN
Reunion Neuroscience recently received Breakthrough Therapy Designation from FDA for its psychedelic based treatment for postpartum depression (PPD)
from BiotechTV - News · host BiotechTV
CEO Greg Mayes describes the science behind luvesilocin, which is a prodrug of 4-OH-DiPT, a psilocybin-like compound, and discusses the company's plans for a phase 3 study. Plus, comments on two other indications the company is pursuing.
NOW PLAYING
Reunion Neuroscience recently received Breakthrough Therapy Designation from FDA for its psychedelic based treatment for postpartum depression (PPD)
No transcript for this episode yet
Similar Episodes
Apr 21, 2026 ·13m
Apr 19, 2026 ·16m
Apr 17, 2026 ·13m
Apr 13, 2026 ·11m
Apr 11, 2026 ·16m